Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ACR-2316 · 1 trial · 1 indication
To determine the MTD of ACR-2316.
To determine the RP2D of ACR-2316, safety and preliminary evaluation of anti-tumor activity
| Arm | Type | Description |
|---|---|---|
| Dose escalation | EXPERIMENTAL | ACR-2316 will be administered using a 3-week or a 4-week schedule. |
| Dose expansion | EXPERIMENTAL | ACR-2316 will be administered using a 3-week schedule. |
| Name | Type | Description |
|---|---|---|
| ACR-2316 | DRUG | ACR-2316 is an experimental drug |
Inclusion Criteria: 1. Signed written informed consent. 2. Histologically or cytologically proven metastatic, recurrent or locally advanced selected solid tumors. 3. Must be willing to provide redacted pathology report and next-generation sequencing (NGS) reports. 4. Subjects should have received n...
ACR-2316 is an investigational small molecule developed by Acrivon Therapeutics, Inc. for the treatment of specific advanced solid tumors. It is in Phase 1 clinical development and is being evaluated in a single recruiting study in the United States. It is not an approved therapy.
ACR-2316 is being studied for the treatment of specific advanced solid tumors in adults. The Phase 1 trial enrolls patients 18 years and older with these tumor types. Because it remains investigational, ACR-2316 is not approved for any use outside of clinical research.
ACR-2316 is being developed by Acrivon Therapeutics, Inc., which trades on the Nasdaq under the ticker ACRV. The company is the sponsor of the Phase 1 study evaluating the small molecule in patients with specific advanced solid tumors.
ACR-2316 is in Phase 1 clinical development. One Phase 1 trial is currently recruiting participants, and no trials of ACR-2316 have been completed. The program has not reached later-stage development, and the drug is investigational rather than approved.
ACR-2316 is being evaluated in the Phase 1 study NCT06667141, titled Study of ACR-2316 in Specific Advanced Solid Tumors. The trial is recruiting, is controlled and randomized, is not double blinded, and plans to enroll approximately 100 participants across sites in the United States.
No. ACR-2316 is an investigational small molecule in Phase 1 clinical development and has not been approved by the FDA. It is available only to participants enrolled in its ongoing clinical trial, which is studying the drug in adults with specific advanced solid tumors.